Greenwich LifeSciences, Inc.
GLSI
$9.53
-$0.33-3.35%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 87.79% | 4.70% | -17.77% | -5.49% | 4.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.66% | 14.67% | 13.71% | 16.06% | 16.01% |
| Operating Income | -71.66% | -14.67% | -13.71% | -16.06% | -16.01% |
| Income Before Tax | -77.57% | -17.45% | -15.30% | -15.78% | -13.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -77.57% | -17.45% | -15.30% | -15.78% | -13.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -77.57% | -17.45% | -15.30% | -15.78% | -13.63% |
| EBIT | -71.66% | -14.67% | -13.71% | -16.06% | -16.01% |
| EBITDA | -71.68% | -14.68% | -13.72% | -16.07% | -16.02% |
| EPS Basic | -74.67% | -15.49% | -13.96% | -14.49% | -12.83% |
| Normalized Basic EPS | -74.68% | -15.47% | -13.91% | -14.44% | -12.81% |
| EPS Diluted | -74.67% | -15.49% | -13.96% | -14.49% | -12.83% |
| Normalized Diluted EPS | -74.68% | -15.47% | -13.91% | -14.44% | -12.81% |
| Average Basic Shares Outstanding | 1.29% | 1.49% | 0.96% | 0.70% | 0.25% |
| Average Diluted Shares Outstanding | 1.29% | 1.49% | 0.96% | 0.70% | 0.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |